Therapeutic Approaches to Histone Reprogramming in Retinal Degeneration

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 854)


Recent data have revealed epigenetic derangements and subsequent chromatin remodeling as a potent biologic switch for chronic inflammation and cell survival which are important therapeutic targets in the pathogenesis of several retinal degenerations. Histone deacetylases (HDACs) are a major component of this system and serve as a unique control of the chromatin remodeling process. With a multitude of targeted HDAC inhibitors now available, their use in both basic science and clinical studies has widened substantially. In the field of ocular biology, there are data to suggest that HDAC inhibition may suppress neovascularization and may be a possible treatment for retinitis pigmentosa and dry age-related macular degeneration (AMD). However, the effects of these inhibitors on cell survival and chemokine expression in the chorioretinal tissues remain very unclear. Here, we review the multifaceted biology of HDAC activity and pharmacologic inhibition while offering further insight into the importance of this epigenetic pathway in retinal degenerations. Our laboratory investigations aim to open translational avenues to advance dry AMD therapeutics while exploring the role of acetylation on inflammatory gene expression in the aging and degenerating retina.


Retinal degeneration Acetylome Lysine deacetylases Histone deacetylases Valproic acid Apoptosis Inflammation Aging Electronic supplementary material 


  1. Alsarraf O, Fan J, Dahrouj M et al (2014) Acetylation: A lysine modification with neuroprotective effects in ischemic retinal degeneration. Exp Eye Res 127C:124–131CrossRefGoogle Scholar
  2. Balaiya S, Khetpal V, Chalam KV (2012) Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2alpha. Mol Vis 18:114–120CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bantscheff M, Hopf C, Savitski MM et al (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29:255–265CrossRefPubMedGoogle Scholar
  4. Berner A, Mohan K, Lou D-Y et al (2014) RPE Cytotoxicity and Caspase Activation after Treatment with Valproic Acid. ARVO Meeting Abstracts 55:5991Google Scholar
  5. Bhalla S, Joshi D, Bhullar S et al (2013) Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. Br J Ophthalmol 97:895–899CrossRefPubMedGoogle Scholar
  6. Biermann J, Grieshaber P, Goebel U et al (2010) Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells. Investigative ophthalmology & visual science 51:526–534Google Scholar
  7. Clemson CM, Tzekov R, Krebs M et al (2011) Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol 95:89–93CrossRefPubMedGoogle Scholar
  8. de Ruijter AJ, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749CrossRefPubMedPubMedCentralGoogle Scholar
  9. Di Marcotullio L, Canettieri G, Infante P et al (2011) Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 1815:241–252PubMedGoogle Scholar
  10. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981–989CrossRefPubMedGoogle Scholar
  11. Ferrante RJ, Kubilus JK, Lee J et al (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 23:9418–9427Google Scholar
  12. Gao L, Cueto MA, Asselbergs F et al (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of biological chemistry 277:25748–25755CrossRefPubMedGoogle Scholar
  13. Glozak MA, Sengupta N, Zhang X et al (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15–23CrossRefPubMedGoogle Scholar
  14. Guzman E, Despande M, Byrd DW et al (2014) Systemic Valproic Acid can Accelerate Photoreceptor Loss in rd10 mice. Invest Ophthalmol Vis Sci 55:1281-CrossRefGoogle Scholar
  15. Imai SI, Guarente L (2014) NAD and sirtuins in aging and disease. Trends in cell biology 24:464–471Google Scholar
  16. Iraha S, Hirami Y, Oota S et al (2014) The efficacy of valproic acid for retinitis pigmentosa patients. ARVO Meeting Abstracts 55:1390Google Scholar
  17. Kim HJ, Chuang DM (2014) HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am J Transl Res 6:206–223PubMedPubMedCentralGoogle Scholar
  18. Kleinman M, Berner A, Lou D et al (2013) Epigenetic Regulation of Eotaxin Expression in Human Retinal Pigment Epithelium. Invest Ophthalmol Vis Sci 54:344-Google Scholar
  19. Kleinman ME, Berner A, Mohan K et al (2014) Histone Deacetylase Expression and Inhibition in Age Related Macular Degeneration. ARVO Meeting Abstracts 55:3457Google Scholar
  20. Kumar A, Kothary PC, Rossi B et al (2014) Valproic Acid Induced Inhibition of Fibroblast Growth Factor 2 Synthesis in Human Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci 55:364-Google Scholar
  21. Lai RYJ, Zong Z, Tam BM et al (2014) Opposing effects of valproic acid treatment in four animal models of retinitis pigmentosa. ARVO Meeting Abstracts 55:4370Google Scholar
  22. Li N, Zhao D, Kirschbaum M et al (2008) HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A 105:4796–4801CrossRefPubMedPubMedCentralGoogle Scholar
  23. Liu XS, Chopp M, Kassis H et al (2012) Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience 220:313–321CrossRefPubMedPubMedCentralGoogle Scholar
  24. Luger K, Mader AW, Richmond RK et al (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260CrossRefPubMedGoogle Scholar
  25. McConkey DJ, White M, Yan W (2012) HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 116:131–163CrossRefPubMedGoogle Scholar
  26. Miao H, Tao Y, Li XX (2012) Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol Vis 18:574–580PubMedPubMedCentralGoogle Scholar
  27. Mitton KP, Guzman EE, Byrd D et al (2012) Rescue Of Photoreceptor Degeneration In Rd1 Mice By Systemic Treatment With Valproic Acid. Invest Ophthalmol Vis Sci 53:5585-CrossRefGoogle Scholar
  28. Murphy SP, Lee RJ, McClean ME et al (2014) MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury. J Neurochem 129:509–515CrossRefPubMedGoogle Scholar
  29. Peserico A, Simone C (2011) Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011:371832CrossRefPubMedPubMedCentralGoogle Scholar
  30. Ren M, Leng Y, Jeong M et al (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358–1367CrossRefPubMedGoogle Scholar
  31. Sancho-Pelluz J, Alavi MV, Sahaboglu A et al (2010) Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death Dis 1:e24CrossRefPubMedPubMedCentralGoogle Scholar
  32. Shakespear MR, Halili MA, Irvine KM et al (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32:335–343CrossRefPubMedGoogle Scholar
  33. Sisk RA (2012) Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. Br J Ophthalmol 96:1154–1155CrossRefPubMedGoogle Scholar
  34. Suuronen T, Nuutinen T, Ryhanen T et al (2007) Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochem Biophys Res Commun 357:397–401CrossRefPubMedGoogle Scholar
  35. Tsolmongyn B, Koide N, Odkhuu E et al (2013) Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-kappaB and inhibition of p53 activation. Cellular immunology 282:100–105CrossRefPubMedGoogle Scholar
  36. van Schooneveld MJ, van den Born LI, van Genderen M et al (2011) The conclusions of Clemson et al concerning valproic acid are premature. Br J Ophthalmol 95:153:153–154 (author reply)CrossRefPubMedGoogle Scholar
  37. Whitcup SM, Sodhi A, Atkinson JP et al (2013) The role of the immune response in age-related macular degeneration. Int J Inflam 2013:348092PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.LexingtonUSA
  2. 2.Department of Ophthalmology and Visual SciencesUniversity of KentuckyLexingtonUSA

Personalised recommendations